Literature DB >> 2156476

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial.

E C Reed1, J L Wolford, K J Kopecky, K E Lilleby, P S Dandliker, J L Todaro, G B McDonald, J D Meyers.   

Abstract

STUDY
OBJECTIVE: To determine the efficacy of ganciclovir for the treatment of cytomegalovirus enteritis after bone marrow transplant.
DESIGN: A randomized, double-blind, placebo-controlled trial.
SETTING: Inpatient units of a cancer center. PATIENTS: Consecutive patients with biopsy-documented cytomegalovirus infection of the gastrointestinal tract. Cytomegalovirus was identified by culture or by immunohistologic or standard histologic analysis.
INTERVENTIONS: Ganciclovir, 2.5 mg/kg body weight every 8 hours for 14 days, or placebo, with dosage adjusted for decreases in renal function. Therapy was discontinued if the neutrophil count or creatinine clearance fell below preset criteria.
MEASUREMENTS AND MAIN RESULTS: Virus cultures of throat, urine, and blood specimens were done before, 3 times weekly during, and weekly for 3 weeks after therapy. Endoscopy was repeated after treatment. Patients were examined, and blood counts, electrolytes, and renal and hepatic function were monitored during therapy. Ganciclovir recipients had cessation of oropharyngeal (P = 0.001) and urinary (P = 0.004) cytomegalovirus excretion and negative cultures of repeat esophageal specimens (P = 0.002) more often than placebo recipients. No difference existed in either clinical symptoms or endoscopic appearance between the groups after treatment. Cytomegalovirus pneumonia occurred in four patients who received ganciclovir and in six who received placebo. One ganciclovir recipient and four placebo recipients were withdrawn from treatment because of neutropenia, but there was no overall difference in the proportional decrease in leukocyte counts between groups.
CONCLUSIONS: Although ganciclovir suppressed cytomegalovirus replication, 2 weeks of treatment was not associated with clinical or endoscopic improvement when compared with supportive care.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156476     DOI: 10.7326/0003-4819-112-7-505

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

2.  Risk factors for cytomegalovirus gastrointestinal diseases in adult patients with cancer.

Authors:  J-H Ko; K R Peck; W J Lee; K Huh; J R Yoo; K Kim; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; Y-H Kim; N Y Lee; K-M Kim; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-23       Impact factor: 3.267

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 4.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 5.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

Review 7.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 8.  Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients.

Authors:  W L Drew
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 9.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

10.  Successful treatment with ganciclovir for cytomegalovirus duodenitis following allogenic bone marrow transplantation.

Authors:  J H Ahn; J H Lee; K H Lee; W K Kim; J S Lee; H Bahng; H Y Jung; Y S Kim; O Kim; S H Kim
Journal:  Korean J Intern Med       Date:  1999-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.